[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0907735T5 - Modulatorer af vævsregenerering - Google Patents

Modulatorer af vævsregenerering

Info

Publication number
DK0907735T5
DK0907735T5 DK97932145.2T DK97932145T DK0907735T5 DK 0907735 T5 DK0907735 T5 DK 0907735T5 DK 97932145 T DK97932145 T DK 97932145T DK 0907735 T5 DK0907735 T5 DK 0907735T5
Authority
DK
Denmark
Prior art keywords
modulators
tissue regeneration
purified
new
nucleic acid
Prior art date
Application number
DK97932145.2T
Other languages
English (en)
Other versions
DK0907735T4 (da
DK0907735T3 (da
Inventor
Michele Sanicola-Nadel
Joseph V Bonventre
Catherine A Hession
Takaharu Ichimura
Henry Wei
Richard L Cate
Original Assignee
Biogen Idec Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26690881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0907735(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc, Gen Hospital Corp filed Critical Biogen Idec Inc
Publication of DK0907735T3 publication Critical patent/DK0907735T3/da
Publication of DK0907735T4 publication Critical patent/DK0907735T4/da
Application granted granted Critical
Publication of DK0907735T5 publication Critical patent/DK0907735T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
DK97932145.2T 1996-05-24 1997-05-23 Modulatorer af vævsregenerering DK0907735T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1822896P 1996-05-24 1996-05-24
US2344296P 1996-08-23 1996-08-23
PCT/US1997/009303 WO1997044460A1 (en) 1996-05-24 1997-05-23 Modulators of tissue regeneration

Publications (3)

Publication Number Publication Date
DK0907735T3 DK0907735T3 (da) 2006-06-26
DK0907735T4 DK0907735T4 (da) 2009-12-21
DK0907735T5 true DK0907735T5 (da) 2010-06-14

Family

ID=26690881

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97932145.2T DK0907735T5 (da) 1996-05-24 1997-05-23 Modulatorer af vævsregenerering

Country Status (27)

Country Link
US (4) US6664385B1 (da)
EP (2) EP1655367A1 (da)
JP (3) JP4602482B2 (da)
CN (1) CN1147584C (da)
AT (1) ATE318903T1 (da)
AU (1) AU712289B2 (da)
BG (1) BG64678B1 (da)
BR (1) BR9709115A (da)
CA (1) CA2257851C (da)
CZ (1) CZ295936B6 (da)
DE (1) DE69735364T3 (da)
DK (1) DK0907735T5 (da)
EA (1) EA004402B1 (da)
EE (1) EE04817B1 (da)
ES (1) ES2258793T5 (da)
HK (1) HK1021746A1 (da)
HU (1) HU226205B1 (da)
IL (1) IL127162A (da)
IS (1) IS2636B (da)
NO (2) NO327597B1 (da)
NZ (1) NZ336467A (da)
PL (1) PL188826B1 (da)
PT (1) PT907735E (da)
SI (1) SI0907735T2 (da)
SK (1) SK285461B6 (da)
TR (1) TR199802421T2 (da)
WO (1) WO1997044460A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655367A1 (en) * 1996-05-24 2006-05-10 The General Hospital Corporation Modulators of tissue regeneration
EP0983357A1 (en) * 1997-05-23 2000-03-08 Biogen, Inc. Modulators of tissue regeneration
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR20010042069A (ko) 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1160321A1 (en) * 2000-05-31 2001-12-05 Sanofi-Synthelabo Kidney Injury Novel Gene-1: Isolation and therapeutic applications
AU6986201A (en) * 2000-06-16 2002-01-02 Biogen Inc Renal regulatory elements and methods of use thereof
US6812002B2 (en) 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
KR20040014997A (ko) 2001-06-29 2004-02-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Ｔ 세포 조절 유전자 및 그것의 사용방법
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
CA2479732A1 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60322744D1 (de) * 2002-12-30 2008-09-18 Biogen Idec Inc Kim-1-antagonisten und verwendung zur immunsystemmodulation
CA2519528C (en) * 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20040219603A1 (en) * 2003-03-27 2004-11-04 Prasad Devarajan Method and kit for detecting the early onset of renal tubular cell injury
US7776824B2 (en) 2004-05-06 2010-08-17 The Trustees Of Columbia University NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
RU2283666C9 (ru) * 2004-05-14 2007-03-10 Бизяев Алексей Вячеславович Средство для активации восстановления структуры и функции поврежденных тканей и органов
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
EP1831699B1 (en) * 2004-12-20 2009-11-11 Antibodyshop A/S Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
EP1865985B1 (en) 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
AU2006315580A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
EP2064553B2 (en) * 2006-08-07 2023-06-07 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090297479A1 (en) * 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
EP3273246A1 (en) * 2008-08-28 2018-01-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5947544B2 (ja) * 2008-08-29 2016-07-06 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CN104020284B (zh) * 2008-10-21 2016-08-24 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP3783363A1 (en) 2008-10-21 2021-02-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592488A (en) 2008-11-10 2012-10-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5735922B2 (ja) * 2008-11-22 2015-06-17 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
ES2530574T3 (es) 2009-01-28 2015-03-03 Ind Tech Res Inst Biomarcadores asociados a la nefropatía
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8871459B2 (en) 2009-08-07 2014-10-28 Astute Medical, Inc. Method for evaluating renal status by determining beta-2-glycoprotein 1
WO2011017614A1 (en) 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725635B (zh) 2009-11-07 2015-05-20 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CA2784889C (en) 2009-12-20 2018-06-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ700695A (en) 2010-02-05 2016-05-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20140051754A (ko) 2010-02-26 2014-05-02 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DK2672980T3 (da) * 2011-02-09 2018-02-26 Lavivo Ab Synbiotiske sammensætninger til genetablering og rekonstitution af tarmmikroflora
EP2788759B1 (en) 2011-12-08 2019-02-20 Astute Medical, Inc. Methods and uses for diagnosis of renal injury and renal failure
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CA3158996C (en) 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
WO2015134671A1 (en) 2014-03-04 2015-09-11 Targeson, Inc. Molecular imaging contrast agents and uses thereof
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1995021922A2 (en) * 1994-02-14 1995-08-17 Abbott Laboratories Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
US5622861A (en) * 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
JPH10508461A (ja) * 1994-08-18 1998-08-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 独特の関連したカポシ肉腫ウイルス配列およびその使用
US6069230A (en) * 1994-11-10 2000-05-30 Promega Corporation High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
EP1655367A1 (en) * 1996-05-24 2006-05-10 The General Hospital Corporation Modulators of tissue regeneration
AU6986201A (en) * 2000-06-16 2002-01-02 Biogen Inc Renal regulatory elements and methods of use thereof
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
KR20040014997A (ko) * 2001-06-29 2004-02-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Ｔ 세포 조절 유전자 및 그것의 사용방법
US7215871B2 (en) * 2001-07-27 2007-05-08 Thomson Licensing Changing a playback speed for video presentation recorded in a field structure format
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
WO2003063792A2 (en) * 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
CA2479732A1 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60322744D1 (de) * 2002-12-30 2008-09-18 Biogen Idec Inc Kim-1-antagonisten und verwendung zur immunsystemmodulation
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
EP1740224A4 (en) * 2004-03-24 2008-07-02 Telos Pharmaceuticals Llc ADJUVANT COMPOSITIONS ENHANCING IMMUNE RESPONSE TO VACCINES AND METHODS OF USE

Also Published As

Publication number Publication date
IL127162A (en) 2007-07-24
EE04817B1 (et) 2007-04-16
PL330313A1 (en) 1999-05-10
DE69735364T2 (de) 2006-11-30
WO1997044460A1 (en) 1997-11-27
CA2257851C (en) 2011-11-15
DK0907735T4 (da) 2009-12-21
NZ336467A (en) 2000-10-27
ATE318903T1 (de) 2006-03-15
HUP9902770A3 (en) 2001-09-28
JP2001505761A (ja) 2001-05-08
ES2258793T5 (es) 2010-01-25
HUP9902770A2 (hu) 1999-12-28
US20060286031A1 (en) 2006-12-21
JP4602482B2 (ja) 2010-12-22
SI0907735T2 (sl) 2010-01-29
CA2257851A1 (en) 1997-11-27
DK0907735T3 (da) 2006-06-26
CZ295936B6 (cs) 2005-12-14
NO985427L (no) 1999-01-25
BG102967A (bg) 2000-05-31
IS2636B (is) 2010-06-15
EA004402B1 (ru) 2004-04-29
JP2009039111A (ja) 2009-02-26
SK160998A3 (en) 1999-07-12
AU3567697A (en) 1997-12-09
ES2258793T3 (es) 2006-09-01
DE69735364D1 (de) 2006-04-27
NO20090945L (no) 1999-01-25
DE69735364T3 (de) 2010-05-06
IL127162A0 (en) 1999-09-22
EP0907735B1 (en) 2006-03-01
PL188826B1 (pl) 2005-04-29
EP0907735A1 (en) 1999-04-14
EP1655367A1 (en) 2006-05-10
HU226205B1 (en) 2008-06-30
EE9800409A (et) 1999-06-15
CN1147584C (zh) 2004-04-28
US20070141590A1 (en) 2007-06-21
EP0907735B9 (en) 2010-05-19
CN1223685A (zh) 1999-07-21
NO327597B1 (no) 2009-08-31
US6664385B1 (en) 2003-12-16
EA199801044A1 (ru) 1999-04-29
JP2008067701A (ja) 2008-03-27
IS4902A (is) 1998-11-20
HK1021746A1 (en) 2000-06-30
TR199802421T2 (xx) 1999-02-22
NO985427D0 (no) 1998-11-20
AU712289B2 (en) 1999-11-04
SK285461B6 (sk) 2007-02-01
PT907735E (pt) 2006-06-30
SI0907735T1 (sl) 2006-08-31
BR9709115A (pt) 1999-08-03
EP0907735B2 (en) 2009-10-07
JP4316640B2 (ja) 2009-08-19
CZ381398A3 (cs) 1999-05-12
US20050089868A1 (en) 2005-04-28
BG64678B1 (bg) 2005-11-30

Similar Documents

Publication Publication Date Title
DK0907735T3 (da) Modulatorer af vævsregenerering
ATE328896T1 (de) Faktor viii vom schwein und hybriden
DE59804095D1 (de) Verfahren zur herstellung von niedermolekularem, hochreaktivem polyisobutylen
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
DE69707849D1 (de) Verfahren zur reinigung von 1,4-butandiol
ATE179986T1 (de) Verfahren zur herstellung von 1-(2'-deoxy-2',2'- difluoro-d-ribofuranosyl)-4-amino-pyrimidin-2-o - hydrochlorid
DE69527803D1 (de) Aufgereinigte dna-polymerase von thermococcus barossii
DE69807962D1 (de) Verfahren zur Reinigung von rohem 1,1,1,3,3-Pentafluorpropan
DE69715234D1 (de) Verfahren zur reinigung von 1,1-difluorethan
DE69710078D1 (de) Verfahren zur reinigung von 1,1,1,3,3-pentafluorpropan
DK0920501T3 (da) Neuritin, et neurogen
FI962087A0 (fi) Olefiinien polymerointiin tarkoitettu stereospesifOlefiinien polymerointiin tarkoitettu stereospesifinen katalyyttisysteemi ja monivaiheiset polymeroiinen katalyyttisysteemi ja monivaiheiset polymerointiprosessit, joissa tätä systeemiä käytetään ntiprosessit, joissa tätä systeemiä käytetään
MX9806041A (es) Proteina purificada sr-p70.
DE59506870D1 (de) Verfahren zur Herstellung von Polyamiden auf Basis von alpha,omega-Dinitrilen
AU3670395A (en) Hippocampus-associated proteins, dna sequences coding therefor and uses thereof
DE59712799D1 (de) Aav-dna mit helfervirus-sequenzen
PE20399A1 (es) Muteina ob
DE69710294D1 (de) Verfahren zur Herstellung von 3,5,5-Trimethyl-Cyclohexa-3-en-1-on
FR2717185B1 (fr) Microfiltration de la bière.
DE69706933D1 (de) Verfahren zur Reinigung von 1,1,1-Tris(4-Hydroxyphenyl)alkanen
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
MA23574A1 (fr) Nouveaux derives alcanes 1,1-bis (heteroazolyl) et leur utilisation comme agents neuro-inhibiteurs
DE69607582D1 (de) Verfahren zur Herstellung und Reinigung von 1,1,1-Tris(4-hydroxyphenyl)ethan
FR2709944B1 (fr) Agrafe chirurgicale.
DE69721065D1 (de) Verfahren zur reiningung von 1,3,5-triisopropylbenzol